AstraZeneca Outsources Drug Discovery Research To BioDuro For Respiratory And Inflammation Indications
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - AstraZeneca is expanding its research collaboration with contract research organization BioDuro to cooperate on drug discovery research in respiratory and inflammation diseases in China, the two companies announced March 23
You may also be interested in...
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.
China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
SHANGHAI - The rapid transformation of China's pharmaceutical and biotech sector reveals the changing face of this nation and the realization that China is more dynamic than developed markets such as the U.S. and Europe and is a good place to try out different models and approaches to R&D, presenters at the China R&D Summit told attendees April 7